Pomalidomide
- Generic Name
- Pomalidomide
- Brand Names
- Imnovid, Pomalyst, Imnovid (previously Pomalidomide Celgene), Pomalidomide Viatris, Pomalidomide Zentiva, Pomalidomide Krka, Pomalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C13H11N3O4
- CAS Number
- 19171-19-8
- Unique Ingredient Identifier
- D2UX06XLB5
- Background
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
- Indication
Pomalidomide is indicated for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and have demonstrated disease progression on or within 60 days of completion of the last therapy. It is also indicated for the treatment of Kaposi's sarcoma (KS) in AIDS patients who have failed highly active antiretroviral therapy (HAART) and for the treatment of KS in HIV-negative patients.
- Associated Conditions
- Kaposi's Sarcoma, Multiple Myeloma (MM)
Clinical Research of Pomalidomide Maintenance Therapy for Primary Multiple Myeloma
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- LanZhou University
- Target Recruit Count
- 15
- Registration Number
- NCT05378971
- Locations
- 🇨🇳
The First Hospital of Lanzhou University, Lanzhou, Gansu, China
Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT05348213
- Locations
- 🇨🇳
Ruijin Hospital, Shanghai, Shanghai, China
A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor
- Conditions
- Neoplasms, Plasma CellParaproteinemiasMultiple MyelomaNeoplasms by Histologic TypeBlood Protein DisordersHematologic DiseasesRenal ImpairmentNeoplasms
- Interventions
- First Posted Date
- 2022-03-28
- Last Posted Date
- 2022-03-28
- Lead Sponsor
- Hellenic Society of Hematology
- Target Recruit Count
- 108
- Registration Number
- NCT05298683
- Locations
- 🇬🇷
General Hospital of Athens "Evangelismos", Athens, Greece
🇬🇷Anticancer Oncology Hospital of Athens "Agios Savvas", Athens, Greece
🇬🇷General Hospital of Athens "Alexandra", Athens, Greece
Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma
- Conditions
- Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell MyelomaSmoldering Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 17
- Registration Number
- NCT05288062
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸Mayo Clinic Hospital in Arizona, Phoenix, Arizona, United States
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- TeneoOne Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05259839
- Locations
- 🇪🇸
Hospital Universitario Virgen del Rocio /ID# 242974, Sevilla, Spain
🇦🇺St George Hospital /ID# 243740, Kogarah, New South Wales, Australia
🇺🇸University of Arkansas for Medical Sciences /ID# 243096, Little Rock, Arkansas, United States
A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
- Conditions
- Multiple MyelomaRecurrent or Refractory
- Interventions
- First Posted Date
- 2022-02-11
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 85
- Registration Number
- NCT05236621
- Locations
- 🇨🇳
Foshan First People's Hospital, Foshan, Guangdong, China
🇨🇳Beijing Chaoyang Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
- Conditions
- Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Emory University
- Target Recruit Count
- 34
- Registration Number
- NCT05208307
- Locations
- 🇺🇸
Emory University/Winship Cancer Institute, Atlanta, Georgia, United States
A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.
- Conditions
- Relapsed Hematologic MalignancyRefractory Hematologic Malignancy
- Interventions
- First Posted Date
- 2022-01-25
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- Epizyme, Inc.
- Registration Number
- NCT05205252
- Locations
- 🇺🇸
Central Care Cancer Center, Bolivar, Missouri, United States
🇺🇸California Cancer Associates For Research And Excellence, cCARE, Santa Fe, California, United States
🇺🇸Astera Cancer Center, East Brunswick, New Jersey, United States
A Multicenter In-class Transition Study of Ixazomib Combined With Pomalidomide and Dexamethasone or With Lenalidomide and Dexamethasone in Adults With Relapsed/Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- Takeda
- Registration Number
- NCT05183139
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2021-11-30
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 317
- Registration Number
- NCT05137054
- Locations
- 🇪🇸
Hospital Clínico Universitario de Santiago, Santiago, A Coruña, Spain
🇺🇸Scripps Clinic Torrey Pines, La Jolla, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.